Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?

Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells,...

Full description

Bibliographic Details
Main Authors: Brigida Anna Maiorano, Martina Catalano, Evaristo Maiello, Giandomenico Roviello
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Oncology
Subjects:
enfortumab vedotin
ADC
antibody-drug conjugate
nectin-4
urothelial carcinoma
bladder cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1254906/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1254906/full

Similar Items